Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul 18.
doi: 10.1681/ASN.0000000776. Online ahead of print.

Effects of Dapagliflozin on Health-Related Quality of Life in Patients with CKD

Wisanne M Bakker  1 , Hiddo J L Heerspink  2   3 , Niels Jongs  2 , Ricardo Correa-Rotter  4 , Peter Rossing  5   6 , Robert D Toto  7 , David C Wheeler  8 , John J V McMurray  9 , Anna Maria Langkilde  10 , Ron T Gansevoort  1 , Glenn M Chertow  11 , Priya Vart  2
Affiliations

Effects of Dapagliflozin on Health-Related Quality of Life in Patients with CKD

Wisanne M Bakker et al. J Am Soc Nephrol. .
No abstract available

Keywords: CKD; chronic kidney disease; chronic kidney failure; chronic renal failure; chronic renal insufficiency; health status; outcomes; patient self-assessment; quality of life; randomized controlled trials.

PubMed Disclaimer

References

    1. Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. New Engl J Med. 2019;380(24):2295–2306. doi: 10.1056/nejmoa1811744 - DOI
    1. Herrington WG, Staplin N, Wanner C, et al.; The EMPA-KIDNEY Collaborative Group. Empagliflozin in patients with chronic kidney disease. New Engl J Med. 2023;388(2):117–127. doi: 10.1056/nejmoa2204233 - DOI
    1. Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. New Engl J Med. 2020;383(15):1436–1446. doi: 10.1056/nejmoa2024816 - DOI
    1. Spiegel BMR, Melmed G, Robbins S, Esrailian E. Biomarkers and health-related quality of life in end-stage renal disease: a systematic review. Clin J Am Soc Nephrol. 2008;3(6):1759–1768. doi: 10.2215/CJN.00820208 - DOI
    1. Ku E, Del Vecchio L, Eckardt KU, et al. Novel anemia therapies in chronic kidney disease: conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference. Kidney Int. 2023;104(4):655–680. doi: 10.1016/j.kint.2023.05.009 - DOI

Associated data

Grants and funding

LinkOut - more resources